What is Upexi?
Upexi, Inc. operates as a diversified brand owner and distributor, specializing in the development of consumer products within the pet, surgery, recovery, skin, beauty, and wellness sectors. Formerly known as Grove, Inc., the company rebranded in 2022 to better align with its expanded mission of delivering high-quality goods through a multi-channel distribution strategy. Its core assets include proprietary brands such as Cure Mashrooms, Lucky Tail, and PRAX, which are distributed via a sophisticated network of wholesale partnerships and major third-party e-commerce platforms. The firm's business model is predicated on operational agility and a deep understanding of consumer trends, allowing it to maintain a resilient presence in the health and wellness markets.
How much funding has Upexi raised?
Upexi has raised a total of $1.1B across 9 funding rounds:
Debt
$16.5M
Multiple Rounds
$1B
Stock/Share Issuance
$19.5M
Debt (2022): $16.5M, investors not publicly disclosed
Other Financing Round (2025): $100M led by Big Brain Creation, Anagram International, and Delphi Ventures
Stock/Share Issuance (2025): $200M, investors not publicly disclosed
Debt (2025): $500M featuring AGP Canada Investments ULC
Private Equity (2025): $200M, investors not publicly disclosed
Stock/Share Issuance (2025): $23M, investors not publicly disclosed
Stock/Share Issuance (2025): $10M, investors not publicly disclosed
Stock/Share Issuance (2025): $10M, investors not publicly disclosed
Stock/Share Issuance (2026): $19.5M, investors not publicly disclosed
Key Investors in Upexi
AGP Canada Investments ULC
A.G.P. Canada Investments ULC specializes in investment banking and capital markets services, focusing on capital raises for public and private companies in the middle market.
Big Brain Creation
Big Brain Creation is an award-winning web design and development company that offers a comprehensive range of services including digital marketing, branding, and video production.
Delphi Ventures
Delphi Ventures is a venture capital firm that has focused on early stage investing in medical devices and biotechnology for two decades.
What's next for Upexi?
Looking ahead, Upexi is poised to utilize its recent capital injection to accelerate its brand acquisition strategy and optimize its supply chain infrastructure. The focus remains on scaling its existing product lines while exploring new market opportunities that align with its core competencies in wellness and recovery. By maintaining a disciplined approach to capital allocation, the company aims to enhance its competitive advantage and drive long-term shareholder value. Future growth will likely be characterized by continued investment in digital marketing capabilities and the expansion of its wholesale distribution network, ensuring that Upexi remains a dominant force in the consumer goods industry.
See full Upexi company page
